Detection of clade 2.3.4.4b highly pathogenic H5N1 influenza virus in New York City
bioRxiv [Preprint]. 2024 Apr 4:2024.04.04.588061. doi: 10.1101/2024.04.04.588061.
PMID:
An ELISA-Based Method to Measure Mucosal Antibody Responses Against SARS-CoV-2 in Human Saliva
Curr Protoc. 2024 Apr;4(4):e1024. doi: 10.1002/cpz1.1024.
PMID:
Anti-SARS-CoV-2 IgG Seroprevalence in Tyrol, Austria, among 28,768 Blood Donors between May 2022 and March 2023
Vaccines (Basel). 2024 Mar 8;12(3):284. doi: 10.3390/vaccines12030284.
PMID:
SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5
Cell Rep Med. 2024 Mar 19;5(3):101474. doi: 10.1016/j.xcrm.2024.101474.
PMID:
Aspergillus-specific IgG antibodies for diagnosing chronic pulmonary aspergillosis compared with the reference standard-author’s reply
Clin Microbiol Infect. 2024 May;30(5):696-697. doi: 10.1016/j.cmi.2024.02.010. Epub 2024 Feb 14.
PMID:
Mycobacterium avium complex pulmonary disease patients with limited treatment options
ERJ Open Res. 2024 Jan 15;10(1):00610-2023. doi: 10.1183/23120541.00610-2023. eCollection 2024 Jan.
PMID:
Chronic Pulmonary Aspergillosis as a Considerable Complication in Post-Tuberculosis Lung Disease
Semin Respir Crit Care Med. 2024 Feb;45(1):102-113. doi: 10.1055/s-0043-1776913. Epub 2024 Jan 9.
PMID:
Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria
Eur J Clin Invest. 2024 Mar;54(3):e14136. doi: 10.1111/eci.14136. Epub 2023 Nov 30.
PMID:
Burden, clinical features, and outcomes of post-tuberculosis chronic obstructive lung diseases
Curr Opin Pulm Med. 2024 Mar 1;30(2):156-166. doi: 10.1097/MCP.0000000000001026. Epub 2023 Oct 30.
PMID:
Aspergillus-specific IgG antibodies for diagnosing chronic pulmonary aspergillosis compared to the reference standard
Clin Microbiol Infect. 2023 Dec;29(12):1605.e1-1605.e4. doi: 10.1016/j.cmi.2023.08.032. Epub 2023 Sep 7.
PMID: